You searched for Antibody candidate - Page 38 of 69

psoriasis treatment approval morphosys 1

News and Trends 23 Nov 2017

Janssen’s Psoriasis Drug is Given a Thumbs Up for Use in Europe

…3-10% or more than 10% of the body is affected. Guselkumab (Tremfya) is a human anti-IL-23 monoclonal antibody developed by Janssen and generated using MorphoSys’s Human Combinatorial Antibody Library (HuCAL)…

November 23, 2017 - 3 minutesmins - By Alex Dale

News and Trends 8 Sep 2022

Integral Molecular joins FDA’s ISTAND program

…by allowing them to be used in regulatory (IND, NDA or BLA) applications without needing the FDA to reconsider and reconfirm their suitability. Integral Molecular said antibodies and antibody-based therapies,…

September 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Jun 2023

Astellas developing new gastric cancer drug

…antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, zolbetuximab would be the first…

June 9, 2023 - 4 minutesmins - By Jim Cornall

In Depth 8 Oct 2024

Top biotech deals of September 2024

…of Clairvoyant’s phase 2 psilocybin candidate being tested for alcohol use disorder. And finally, U.S.-based cancer company OncoC4 joined forces with AcroImmune to add an Investigational New Drug Application (IND)-ready…

October 8, 2024 - 6 minutesmins - By Roohi Mariam Peter

News and Trends 16 Dec 2022

Alchemab Therapeutics receives £1.7M grant to work on therapy for Huntington’s disease

…to accelerate development of our antibody and deliver some hope for patients.” This is the second grant awarded to Alchemab and MDC. The financing will support preclinical development of the…

December 16, 2022 - 3 minutesmins - By Jim Cornall

More News! 17 Oct 2022

Clinical trial of treatment for advanced solid tumors approved

…about a phase 1b/2 clinical trial of its in-house developed Ivonescimab (PD-1/VEGF bi-specific AK112) combined with Drebuxelimab (CD73, AK119). AK112 is the first PD-1/VEGF bi-specific antibody that entered phase 3…

October 17, 2022 - 2 minutesmins - By Liza Laws

geneuro multiple sclerosis neuron viral dna

News and Trends 12 Mar 2019

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

An antibody that blocks the action of a hidden viral protein encoded by our genome shows encouraging signs of slowing down the progression of multiple sclerosis, according to the Swiss…

March 12, 2019 - 3 minutesmins - By Jonathan Smith

numab intarcia antibodies implantable drug delivery

News and Trends 6 Jun 2016

Swiss-US Implant could make taking pills obsolete in Autoimmune Diseases

…through other methods. Numab then engineers these antibody’s variable domain (the part of the antibody with binds to antigen) to make it more stable and then uses it as a…

June 6, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 15 Oct 2020

Swiss Biotech Launches Amidst Hot Streak for Rare Autoimmune Disease

…approach to Alexion and the other antibody developers, whose drugs require intravenous injection. The company also targets another rare neuromuscular condition, myasthenia gravis, with the same drug candidate. “Chord Therapeutics…

October 15, 2020 - 3 minutesmins - By Helen Albert

pure biologics wroclaw devics disease 1 1

Startup Scout 31 May 2019

This Biotech Treats a Neurological Autoimmune Disorder Using DNA

…begin clinical trials in 2023. Pure Biologics also has a separate program developing an antibody drug that binds two targets at once, called a bispecific antibody. Although there are other…

May 31, 2019 - 4 minutesmins - By Jonathan Smith

News and Trends 28 Sep 2018

Roche Acquires UK Cancer Immunotherapy Biotech in Deal Worth up to €655M

…cells called regulatory T cells. These cells hold back the immune system from attacking tumors, thus the antibody helps the patient’s immune system to fight the cancer. The antibody has…

September 28, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 16 Feb 2023

Maxion Therapeutics raises $16M to target GPCRs

…co-founded CAT (acquired by AstraZeneca for £700 million) and IONTAS (acquired by FairJourney Biologics). At CAT, McCafferty co-invented antibody phage display, the technology used to discover the world’s best-selling drug,…

February 16, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

Janssen’s Psoriasis Drug is Given a Thumbs Up for Use in Europe

Integral Molecular joins FDA’s ISTAND program

Astellas developing new gastric cancer drug

Top biotech deals of September 2024

Alchemab Therapeutics receives £1.7M grant to work on therapy for Huntington’s disease

Clinical trial of treatment for advanced solid tumors approved

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

Swiss-US Implant could make taking pills obsolete in Autoimmune Diseases

Swiss Biotech Launches Amidst Hot Streak for Rare Autoimmune Disease

This Biotech Treats a Neurological Autoimmune Disorder Using DNA

Roche Acquires UK Cancer Immunotherapy Biotech in Deal Worth up to €655M

Maxion Therapeutics raises $16M to target GPCRs

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!